openFDA
Cure8 regulatory brief
Adalimumab FDA label update (2026-07-08)
Medications
Adalimumab
Anti-TNF
Regulatory Update
Patients On Biologics
Adult patients
Pediatric Patients
Clinicians
Why This Matters
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
Who Should Pay Attention
Adult and pediatric IBD patients on or considering adalimumab, caregivers, prescribing clinicians, pharmacists
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This label lists approved uses including treatment of moderately to severely active Crohn’s disease (adults and children 6 years and older) and ulcerative colitis (adults).
It highlights the boxed warning about increased risk of serious infections and malignancies with TNF blockers and advises testing for latent TB before starting therapy and monitoring during treatment.
The label also notes limitations of use (effectiveness not established in patients who have lost response to or were intolerant to TNF blockers) and other standard safety information such as risks of invasive fungal infections and reports of rare hepatosplenic T‑cell lymphoma in adolescents/young adults with IBD treated with TNF blockers.
Keep In Mind
This entry is a regulatory drug‑label update (U.S. prescribing information). It outlines approved uses and safety warnings; it is not a clinical guideline or new trial result.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 8, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ABRILADA FDA label update (2026-06-18)
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
TNF inhibitors might help prevent serious complications in kids with Crohn's Disease
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...